Scienceline Publications Journal of Life Science and Biomedicine 2251-9939 11 5 2021 September Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19 80 87 https://jlsb.science-line.com/attachments/article/87/JLSB%2011(5)%2080-87,%202021-Dexmedetomidine%20for%20psychoemotional%20disorders%20in%20COVID-19%20patients.pdf https://dx.doi.org/10.51145/jlsb.2021.10 EN Ravshan Aliyevich IBADOV Intensive Care Unit, Republican Specialized Scientific-Practical Medical Center of Surgery Named after Academician V.Vakhidov, Tashkent, Uzbekistan Anvar Shamkhatovich ARIFJANOV Intensive Care Unit, Republican Specialized Zangiota-1 Hospital for COVID-19, Tashkent region, Uzbekistan Sardor Khamdamovich IBRAGIMOV Intensive Care Unit, Republican Specialized Scientific-Practical Medical Center of Surgery Named after Academician V.Vakhidov, Tashkent, Uzbekistan Begali Bobokulovich KHAKIMOV Intensive Care Unit, Republican Specialized Zangiota-2 Hospital for COVID-19, Tashkent region, Uzbekistan Introduction. Most patients with COVID-19 require respiratory support and or mechanical ventilation, long-term use of high doses of sedatives, most of which should be considered in the context of the unique pathophysiology of COVID-19 and associated psychological and neurological disorders. Objective. The objective of this study was to evaluate sedation therapy effectiveness in critically ill patients with severe COVID-19 who received dexmedetomidine compared to propofol. COVID-19 Intensive care unit Depression Anxiety Posttraumatic stress Disorder Sedation Dexmedetomidine Comparison study